Humacyte, Inc.

Humacyte, Inc. is a commercial-stage biotechnology platform company dedicated to developing and manufacturing universally implantable, bioengineered human tissues and organs. Headquartered in Durham, North Carolina, the company's mission is to transform medical practice and improve patient lives by providing off-the-shelf regenerative tissues that do not require patient matching. Humacyte was established in 2004 and became a publicly traded entity in 2021 through a SPAC merger with Alpha Healthcare Acquisition Corp..

The company's flagship product is Symvess™ (acellular tissue engineered vessel-tyod), also referred to as the Human Acellular Vessel (HAV) or Acellular Tissue Engineered Vessel (ATEV™). Symvess™ received FDA approval for vascular trauma repair in December 2024, marking a significant transition for Humacyte from a clinical-stage to a commercial-stage company. Beyond vascular trauma, Humacyte's pipeline includes product candidates in various stages of development for arteriovenous access for hemodialysis, peripheral arterial disease (PAD), coronary artery bypass grafting (CABG), and pediatric heart surgery. The company is also exploring advanced organ systems and tissue constructs, such as bioengineered esophagus, trachea, and urinary conduits.

Recent developments include the commercial launch of Symvess™ in 2025, with reported product revenue of $1.4 million for the full year 2025. In April 2026, Humacyte appointed Jim Mercadante as Chief Commercial Officer and regained exclusive distribution rights for Symvess™ outside the U.S. from Fresenius Medical Care. The company also announced new U.S. Department of Defense funding for bioengineered blood vessels in February 2026 and the Israeli Ministry of Health's acceptance of a Marketing Authorization Application for Symvess™ for vascular trauma repair in March 2026. Dr. Laura E. Niklason, the company's founder, has served as President and CEO since 2020, leading Humacyte's efforts to establish itself as a leader in regenerative medicine.